Login
Companies $SMMT
$11.90 +$0.08 (0.68%) After hours
Summit Therapeutics Inc. logo

Summit Therapeutics Inc.

smmttx.com

What Do They Do?

Develops ivonescimab, an investigational cancer medicine, for patients with lung and colorectal cancers.

Who Are Their Customers?

The company is developing ivonescimab for patients with lung and colorectal cancers; its current work is focused on clinical trials rather than commercial sales.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +10% (Loss)
vs −$231.8M in Q3 FY2025
  • Sep 28, 2026 AstraZeneca agreed to invest $2.0 billion and collaborate on cancer drug trials. The companies will study ivonescimab with sonesitatug vedotin in gastrointestinal cancers and plan broader combination trials.
  • Aug 5, 2026 Summit expanded ivonescimab trials into bladder cancer. The planned global Phase II/III trial will compare ivonescimab plus enfortumab vedotin with pembrolizumab plus enfortumab vedotin.

Focus shifted to oncology The older report described a pipeline that included antibiotics for drug-resistant infections and ridinilazole for C. difficile, alongside the new ivonescimab license. The latest report centers the business on developing ivonescimab for cancer.

Who Do They Compete With?

Competes with BioNTech, Bristol Myers Squibb, Pfizer, Merck &, AbbVie, AstraZeneca, Daiichi Sankyo, and Johnson & Johnson

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support